<i>N</i>‑Fluorobenzenesulfonimide Based Functionalization of C₆₀

The reaction of <i>N</i>-fluoro­benzene­sulfonimide (NFSI) with C₆₀ and exploration of the product as a precursor for various 1,2- and 1,4-bisfullerene adducts are reported. NFSI is also found to act as an oxidant in the reaction of C₆₀ with cyclic amines such as pyrrolidine yielding tetra­amino­aziridino adducts

Preparation of Azafullerene C₅₉NR₅ and Fullerene Derivative C₆₀NAr₅ with a Pyridine Moiety on the Cage Skeleton

[60]­Fullerene hexaadducts C₆₀R₅Cl (R = OMe or Ar) reacted with hydroxylamine to form C₆₀R₅(NHOH) with the hydroxylamino group attached on the central pentagon as in the starting material. Further reactions including treatment with PCl₅ and basic alumina led to the insertion of the nitrogen atom into the fullerene cage skeleton and decarbonylation to form azafullerenes C₅₉N­(H)­(OMe)₄ and C₅₉N­(OMe)₅. The fullerene derivatives C₅₉N­(CO)­R₅ and C₆₀NAr₅ with a pyridinone and a pyridine moiety on the cage skeleton, respectively, were also synthesized starting from the hydroxylamine adducts

Preparation of Azafullerene C₅₉NR₅ and Fullerene Derivative C₆₀NAr₅ with a Pyridine Moiety on the Cage Skeleton

[60]­Fullerene hexaadducts C₆₀R₅Cl (R = OMe or Ar) reacted with hydroxylamine to form C₆₀R₅(NHOH) with the hydroxylamino group attached on the central pentagon as in the starting material. Further reactions including treatment with PCl₅ and basic alumina led to the insertion of the nitrogen atom into the fullerene cage skeleton and decarbonylation to form azafullerenes C₅₉N­(H)­(OMe)₄ and C₅₉N­(OMe)₅. The fullerene derivatives C₅₉N­(CO)­R₅ and C₆₀NAr₅ with a pyridinone and a pyridine moiety on the cage skeleton, respectively, were also synthesized starting from the hydroxylamine adducts

Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Supplementary figures and tables.

Supplementary Figures 1-8 Supplementary Tables 1-13</p

Additional file 5 of Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Additional file 5: Table S1. 40 chemokines included in the Bio-Plex Pro Human Chemokine Panel. Table S2. The primer sequences used for RT-qPCR detection. Table S3. Target sequences for siRNAs. Table S4. Clinical characteristics of patients with different CCL20 expression. Table S5. The interaction molecules of 12 chemokines downloaded from BioGRID databas

Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Supplementary materials.

Supplementary figures 1-12 Supplementary tables Prisma checklist</p

Additional file 3 of Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Additional file 3: Figure S3. The functional enrichment and TCGA cohort analysis of chemokines related to crizotinib efficacy. (A) Biological processes (BPs) enriched among the interaction molecules of 12 chemokines; (B) Angiogenesis-related BPs enriched among the interaction molecules by Cytoscape; (C) The mRNA expression of 4 chemokines between lung adenocarcinoma (LUAD), lung squamous carcinoma (LUSC), and normal tissue from the GEPIA database; (D) Kaplan-Meier curves of disease-free survival (DFS) and overall survival (OS) for CCL20 mRNA expression in TCGA cohort. * p < 0.05

Additional file 4 of Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Additional file 4: Figure S4. The functional enrichment and GEPIA analysis of significant genes and the results of cell apoptosis assay. (A) Angiogenesis-related BPs enriched among the differentially expressed genes from GSE94089 dataset by Cytoscape; (B) Effect of si-CCL2, si-CCL20, si-CCL24, and si-CX3CL1 treatments on cell apoptosis in H3122CR; (C) GEPIA correlation analysis for CCL20 with VEGFA, IL6, CCL2, and CCL24. ns: not significant

Additional file 1 of Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Additional file 1: Figure S1. Kaplan-Meier survival analysis of 9 significant chemokines with progression-free survival (PFS). (A) CCL15; (B) MIF; (C) CCL24; (D) CXCL9; (E) CXCL13; (F) IFN-gamma; (G) IL-6; (H) IL-8; (I) IL-10

Additional file 2 of Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Additional file 2: Figure S2. Kaplan-Meier survival analysis of 5 significant chemokines with overall survival (OS) and time-dependent operating characteristic curve (ROC) of CCL20. (A) IL-8; (B) CCL24; (C) CXCL9; (D) CXCL13; (E) IL-6; Time-dependent operating ROC of CCL20 (F) for progression-free survival (PFS); (G) for OS